Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory Microenvironment through NLRP3 Inhibition

Figure 5

Cryptotanshinone (CTS) inhibited lipopolysaccharide (LPS)-induced bladder cancer cell malignant behaviors in a dose-dependent manner. In total, 5,637 cells were grown and pretreated with LPS, then treated with CTS, and finally subjected to the (a) CCK-8 assay, (b and c) colony formation assay, (d and e) transwell invasion assay, (f and g) wound healing assay, and (h and i) Western blot analysis of cyclin D1, CDK4, MMP-2, MMP-9, E-cadherin, and vimentin proteins. DMSO, dimethyl sulfoxide. , , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)